Introducing the fact that healing is aided by deliberate use of the subconscious.
Self improvement follows!
Psycho-neuro-immunology has been proved by medical scientists and is a specific self-improvement technique.
The fighting cell in the immune system (the T4 cell) is increased in meditation using guided imagery and visualization.
The end result is using the subconscious mind deliberately.
The average walker takes about 10,000 steps per day, which can put tremendous stress on the 26 bones and 33 joints in your feet. The Look for the “O” campaign from the American Orthopaedic Foot & Ankle Society (AOFAS) encourages consumers to take charge of their foot and ankle health and choose a foot and ankle orthopaedic surgeon when medical care is needed.
“Most people don’t give much thought to their foot health – that is, until something goes wrong,” stated J. Chris Coetzee, MD, president of the AOFAS Board of Directors. “But 75% of all people experience foot pain at some point in their lives, and it’s important to know how to find the best medical care before a problem arises.”
To view the multimedia release go to:
https://www.multivu.com/players/English/8164351-aofas-what-is-a-foot-and-ankle-orthopaedic-surgeon/
Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: SAN and NYSE: SNY), announced today that its first doses of Fluzone® (Influenza Vaccine) for the 2016-2017 influenza (“flu”) season have been released by the U.S. Food and Drug Administration (FDA) for shipment. This represents the first of more than 65 million total doses of seasonal influenza vaccine manufactured by Sanofi Pasteur that will be delivered to U.S. health care providers and pharmacies beginning in July and continuing throughout the remainder of the year. Sanofi Pasteur plans to increase its supply to respond to the shifting pediatric public health needs.
Seasonal influenza activity typically occurs between October and May and peaks between December and February. However, influenza activity peaked noticeably late last season occurring in early March 2016.1 Influenza seasons are always unpredictable as new influenza strains emerge and strain activity fluctuates throughout the year, making timely vaccination even more important to help protect against the virus, especially for seniors, young children and infants six months of age and older.
To view the multimedia release go to:
http://www.multivu.com/players/English/7842051-sanofi-pasteur-influenza-vaccine/
Today, Church & Dwight, Co., Inc., the makers of First Response™ pregnancy and ovulation tests, announced the launch of First Response™ Pregnancy PRO Digital Pregnancy Test & App Access – their latest innovation and the first and only Bluetooth Smart-enabled pregnancy test on the market. First Response™ Pregnancy PRO connects to a woman’s smart device through a mobile application. Once synced, the app provides her with pregnancy-related content only available with Pregnancy PRO, and delivers a personalized user experience throughout her entire pregnancy journey.
“We are thrilled to be unveiling the next generation of in-home pregnancy testing on a stage like CES, where so many technological advancements have made their debut,” said Stacey Feldman, Vice President of Marketing, Church & Dwight. “With Pregnancy PRO, we’ve leveraged unique consumer insights to develop a product that not only revolutionizes the pregnancy test category, but more importantly, provides women with the information they need during their journey.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7725251-first-response-pregnancy-pro/
Many women don't realize aging makes heart disease likelier. To combat this problem, teams from Brookdale senior living communities nationwide are fanning out to personally alert women 65 and over to their increased risk and provide resources to fight it. The company hopes to reach 10,000 older women through “10,000 Heart to Hearts,” beginning Feb. 1.
“Cardiac disease kills more women than all cancers combined,” said Brookdale chief medical officer Kevin O'Neil, M.D., F.A.C.P. “On average, women develop heart disease 10 years later than men, with their first heart attack occurring at age 70.”
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7087732-brookdale-senior-living/
https://nationlife.net/enjoy-eating-without-the-fear-of-choking-with-lifevac-review/
LifeVac is a patented life-saving device that is proven to be the most effective way to help a child or adult during a choking emergency.
Place LifeVac over the mouth and nose to create a seal. The one-way valve prevents air from pushing food or objects downward when pressed. Then simply pull to create a one-way suction to remove the lodged food or object in seconds.
LifeVac gives you peace of mind knowing you’re always prepared and your loved ones are protected – because every second matter.
Recommended by hundreds of doctors and medical professionals around the world. Over 100,000 sold in over 40 countries and counting!
Is your life or your child’s life, worth LESS than 100 bucks to you? This product is absolutely worth every penny. And I’ll be still very happy to have bought it, even if I don’t ever get to use it. I know it is there if I ever need it. This thing is absolutely fantastic. I’ve practiced a few times and from what I saw, it can very well save a life, in those critical few minutes you have, before the person becomes so deprived from oxygen and ultimately dies. Very easy to use. I’m grateful for it.
Always Be Prepared. Get LifeVac Today.
Inspire Medical Systems, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved Inspire Upper Airway Stimulation (UAS) therapy for use in a subset of patients with moderate to severe Obstructive Sleep Apnea (OSA) who are unable to use Continuous Positive Airway Pressure (CPAP). Inspire therapy is a fully implanted neurostimulation device, the first of its kind for sleep apnea, that provides an alternative treatment that is proven, convenient and easy to use.
To view the Multimedia News Release, go to: http://www.multivu.com/mnr/7169651-fda-approves-inspire-upper-airway-stimulation-therapy-sleep-apnea
Thirty-six million Americans suffer from migraines, leading to more than $20 billion in medical expenses and costs related to lost productivity each year¹. In recognition of National Migraine Awareness Month and the significant unmet medical needs of migraine patients, Zogenix, Inc. (NASDAQ: ZGNX) is highlighting the importance of selecting the appropriate medication for a patient’s “treatment toolbox” to address specific types of migraine episodes.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/zogenix/50344/
“Explore Your Treatment Options,” a new multimedia ad campaign announced today by the U.S. Department of Health and Human Services’ Agency for Healthcare Research and Quality (AHRQ) and the Ad Council, encourages patients to become more informed about their options before choosing a treatment for a health condition or illness.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/adcouncil/50583/
Chiasma, Inc., a U.S. privately–held biopharma company developing octreotide capsules for the orphan condition acromegaly, today announced two new studies presented at the 97th Endocrine Society (ENDO) Annual Meeting in San Diego, Calif. The studies provide additional data from Chiasma’s Phase III trial and new findings on the patient burden of current injection therapies.
“We now have data to help clinicians determine whether octreotide capsules, if approved, are likely to help their patient with acromegaly maintain response,” said Shlomo Melmed, M.D., senior vice president and dean, Cedars–Sinai Medical Center, Los Angeles and global study principal investigator. “Furthermore, the Phase III results show the safety and efficacy of octreotide capsules can be reliably determined within 12 weeks of initiating therapy.”
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7436451-endo-chiasma-clinical-data/
The Center For Aesthetics
https://thecenterforaesthetics.com
800-575-8337 ~ The CFA Exclusive Evernal Series - Complexion Perfection, laser skincare and hydrafacials. CFA Beauty the premier aesthetic medical centers in Scottsdale, Jackson Hole, Idaho Falls.
Ethicon*, a trusted leader in advancing wound closure, announces the launch of STRATAFIX™ Spiral PDS Plus and STRATAFIX™ Spiral Monocryl Plus Knotless Tissue Control Devices. With the addition of these two new suture technologies to the STRATAFIX™ Family of Knotless Tissue Control Devices, Ethicon has established the most comprehensive and unmatched knotless suture offering available to surgeons in the U.S.
STRATAFIX™ Knotless Tissue Control Devices transforms the wound closure experience by providing unique advantages over traditional sutures. STRATAFIX™ sutures provide more strength and security, more consistency and more efficiency than traditional suturing. The portfolio of knotless sutures also enables surgeons to more easily manage tension and control tissue approximation with each pass during closure and eliminates the need to tie knots.
To view the multimedia release go to:
http://www.multivu.com/players/English/7889651-ethicon-new-stratafix-suture/
